Ranibizumab Implant (Susvimo®)

Approval is not recommended for Susvimo due to significant safety concerns (Boxed Warning for endophthalmitis); use is limited to the FDA‑approved indication and non‑FDA uses are not supported. Key requirements: patient must have neovascular (wet) AMD with documented response to at least two prior intravitreal anti‑VEGF injections, with documentation of diagnosis, prior treatment dates/agents/evidence of response, and acknowledgement of the safety risks.

"Susvimo is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular ..."

Sign up to see full coverage criteria, indications, and limitations.